[ FDA WARNING LETTERS ]

What the FDA is calling out, in writing.

Warning Letters are the FDA’s formal notice that a firm is significantly out of compliance — inspection-readiness gold. SPEQ tracks every letter back to 2021 by date and recipient, and adds the issuing office, subject and a link to the full text for the recent window FDA still publishes in full.

2,252
Letters tracked
Sep 8, 2026
Most recent
7
Issuing offices
across the 46 letters FDA still publishes in full; older rows carry a date and recipient only.
Center for Drug Evaluation and Research (CDER) · 23Office of Inspections and Investigations · 8Center for Veterinary Medicine · 5Center for Devices and Radiological Health · 3Human Foods Program · 3

How to use this library

Narrow by year — every letter back to 2021 carries a date and recipient. For the recent window, filter by issuing office too: CDER writes to drug manufacturers, CDRH to device makers. Rows from that window open with the subject and a link to FDA’s own published letter.

Warning letters are FDA records reproduced as published; SPEQ adds no interpretation. A letter states the Agency’s position at the time of issue and does not by itself establish a final determination. Older archive rows carry a date and recipient only.

New to GxP? Start with Navigator →
60 warning letters
Newest first
COMPLETE INDEX — ALL 60 WARNING LETTER

Every count on this page is derived from the fda_warning_letters table at render — none is a literal. Follow each source link for FDA’s authoritative letter.

Source: U.S. FDA Warning Letters (fda.gov), scraped and refreshed daily. Warning letters are FDA records reproduced as published — SPEQ adds no interpretation. The archive builds forward from the first scan.